Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Michele Donato, MD, Ana Aleman, MD, Donna Weber, MD, Michael Wang, MD, Muzaffer Qazilbasch, MD, Marilyn Davis, R.N., Linda Roden, MD, Floralyn Mendoza, BS, Richard Champlin, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 1177.

https://doi.org/10.1182/blood.V106.11.1177.1177

Published: 2005

Journal Articles

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Erica Campagnaro, MD, Rima Saliba, Ph.D, Karen Anderson, Ph.D, Linda Roden, MD, Floralyn Mendoza, BS, Ana Aleman, MD, Charles Cleeland, Ph.D, Donna Weber, MD, Jane Brown, RN, Sergio Giralt, MD

Blood (2005) 106 (11): 1771.

https://doi.org/10.1182/blood.V106.11.1771.1771

Published: 2005

Journal Articles

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Anna Christoforidou, MD, Patricia Williams, RN, Linda Roden, MD, Ana Aleman, MD, Donna Weber, MD, Floralyn Mendoza, BS, Donald Podoloff, MD, Hazel Breitz, MD, Raymond Alexanian, MD, Richard Champlin, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 426.

https://doi.org/10.1182/blood.V106.11.426.426

Published: 2005

Journal Articles

Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.

Muzaffar H. Qazilbash, MD, Rima Saliba, PhD, Marcos de Lima, MD, Daniel Couriel, MD, Chitra Hosing, MD, Ana Aleman, X Lei, Richard E. Champlin, MD, Sergio A. Giralt, MD

Blood (2004) 104 (11): 3329.

https://doi.org/10.1182/blood.V104.11.3329.3329

Published: 2004

Journal Articles

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Sergio Giralt, MD, Ana Aleman, MD, Xin Lei, MD, Marilyn Davis, RN, Kerry Mickler, RN, Donna Weber, MD, Michael Wang, MD, Richard Champlin, MD

Blood (2004) 104 (11): 1651.

https://doi.org/10.1182/blood.V104.11.1651.1651

Published: 2004

NARROW

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Email alerts

ASH Publications

American Society of Hematology

Transplant Outcomes after Topotecan-Melphalan-Cyclophosphamide (TMC) Conditioning for Autologous Stem Cell Transplantation for Multiple Myeloma. Comparison to Melphalan 200 mg/M2 (MEL200).

Risk Factors for Development of Symptoms Post Autologous Transplant for Multiple Myeloma.

Impact of Holmium-DOTMP on Transplant Outcomes. Results of a Retrospective Single Institution Analysis.

Second Autologous or Allogeneic Transplantation after the Failure of First Autograft in Multiple Myeloma.

Results of Bortezomib (BTZ) Therapy for Myeloma (MM) Patients Relapsing after an Allogeneic Transplant. Preliminary Results Show Efficacy without Induction of GVHD.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only